Prospector Partners LLC Has $11.57 Million Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Prospector Partners LLC grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 20.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 160,491 shares of the medical equipment provider’s stock after purchasing an additional 27,786 shares during the quarter. Prospector Partners LLC’s holdings in Hologic were worth $11,570,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Federated Hermes Inc. increased its holdings in Hologic by 35.8% during the fourth quarter. Federated Hermes Inc. now owns 7,720 shares of the medical equipment provider’s stock worth $557,000 after buying an additional 2,036 shares during the last quarter. Resona Asset Management Co. Ltd. acquired a new position in shares of Hologic during the 4th quarter worth about $6,090,000. Prudential PLC raised its holdings in shares of Hologic by 4.5% in the 4th quarter. Prudential PLC now owns 87,841 shares of the medical equipment provider’s stock valued at $6,332,000 after purchasing an additional 3,819 shares during the period. Westpac Banking Corp raised its holdings in shares of Hologic by 24.9% in the 4th quarter. Westpac Banking Corp now owns 41,173 shares of the medical equipment provider’s stock valued at $2,968,000 after purchasing an additional 8,200 shares during the period. Finally, Bryce Point Capital LLC acquired a new stake in Hologic in the 4th quarter valued at about $488,000. Institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

HOLX has been the topic of several research analyst reports. Citigroup dropped their price objective on Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Needham & Company LLC downgraded Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target for the company. in a report on Monday, February 3rd. Leerink Partners cut shares of Hologic from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Raymond James reissued an “outperform” rating and issued a $90.00 price objective (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Finally, BNP Paribas raised shares of Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $84.62.

Hologic Trading Down 1.3 %

HOLX opened at $60.86 on Friday. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a twelve month low of $59.06 and a twelve month high of $84.67. The stock has a market capitalization of $13.66 billion, a price-to-earnings ratio of 19.20, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a 50-day simple moving average of $64.30 and a 200 day simple moving average of $72.59.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.